IKBKB and lung cancer: In animal models of lung cancer, bortezomib and IKKβ inhibitors caused resistance or paradoxical tumor promotion via development of secondary mutations, NF-κB inhibition in myeloid cells, or enhanced IL-1β secretion by tumor-associated neutrophils through an unknown mechanism15,16,53.